Introduction
============

There is currently no accurate method of measuring the glomerular filtration rate (GFR) during acute kidney injury (AKI). Four-hour creatinine clearance (4-CrCl) is often used. We have previously validated a method of measuring the GFR using a continuous infusion of low-dose iohexol (CILDI) in patients with stable renal function (GFR from normal to \<30 ml/minute/1.73 m^2^). Steady state was achieved in \<10 hours in all subjects and we calculate that variations \>10.3% suggest an AKI. In this study we compare GFR measured by CILDI with 4-CrCl and 1-hour creatinine clearance (1-CrCl).

Methods
=======

Critically ill patients with evolving AKI and patients following nephrectomy were recruited. Demographics were compared using the *t*test. CIDLI was connected for up to 72 hours. Plasma and renal iohexol and creatinine concentrations were measured by tandem mass spectrometry four times daily. Iohexol renal clearance (IRC) and 1-CrCl and 4-CrCl were calculated and compared using Bland-Altman analysis.

Results
=======

Baseline estimated GFR was similar in the postnephrectomy (88 ± 28) to the evolving AKI group (92 ± 23), *P*= 0.70. The evolving AKI group had a higher APACHE score (17.8 ± 5.1 vs. 10.6 ± 3.9; *P*\< 0.001). When 1-CrCl was compared with IRC, a bias of 0.8% (SD 26%, limits of agreement -52 to 50%; Pearson\'s *r*= 0.90) was observed in the evolving AKI group, whereas bias was -3.3% (SD 16, limits of agreement -35 to 29%; Pearson\'s *r*= 0.95) in the postnephrectomy group. When 4-CrCl was compared with IRC, bias was 5.1% (SD 54, limits of agreement -102 to 112%, Pearson\'s *r*= 0.45) in the established AKI group and bias was -4.5% (SD 38, limits of agreement -79 to 70%; Pearson\'s *r*= 0.78) in the postnephrectomy group.

Conclusion
==========

Our data suggest that 4-CrCl is not as accurate and precise as 1-CrCl in patients with AKI and following nephrectomy. IRC appears to be more accurate and precise in patients with a predicted AKI risk and outcome (post nephrectomy) than in patients with evolving AKI. We hypothesise that IRC will be useful alternative to creatinine-based measures of AKI.
